Consensus Pulmonx Corporation

Stocks

LUNG

US7458481014

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-07 EDT			5-day change	1st Jan Change
2.040 ^USD	-0.49%		+25.15%	-7.69%

07-29	Pulmonx Corporation, Q2 2026 Earnings Call, Jul 29, 2026
07-29	Pulmonx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Pulmonx Corporation

Evolution of the Target Price: Pulmonx Corporation

Changes in Analyst Recommendations: Pulmonx Corporation

648613b30210.ayei7NCvyqm2KGIC1G3pXSGGZoITY_mCOwaDuzra9ZY.I2rQm7bNmJjeTVJ05xnfOXnUFrR3ArLhXjX71GqJnO4IbeOtnNurx_xLNw~356ccfa48c4cdaf1c891d02528b126d8

Analysts' recommendations: Pulmonx Corporation

25-07-31	Piper Sandler Downgrades Pulmonx to Neutral From Overweight, Adjusts Price Target to $2.50 From $9	MT
25-07-30	Pulmonx Q2 revenue up 15%, beats expectations, cuts FY revenue forecast	RE
24-12-11	Citigroup Downgrades Pulmonx to Neutral From Buy, Cuts Price Target to $7.50 From $17	MT
24-06-04	Lake Street Initiates Pulmonx With Buy Rating, $12 Price Target	MT
24-02-23	Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16	MT
24-02-22	Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating	MT
24-02-22	Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating	MT
24-02-22	Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating	MT
24-02-22	Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating	MT
24-02-22	Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating	MT
23-09-05	Craig-Hallum Initiates Pulmonx at Buy With $18 Price Target	MT
23-07-11	Citigroup Raises Price Target on Pulmonx to $16 From $14, Maintains Buy Rating	MT
23-05-03	Piper Sandler Adjusts Pulmonx's Price Target top $15 From $13, Keeps Overweight Rating	MT
23-05-03	Morgan Stanley Adjusts Pulmonx's Price Target to $14 From $11, Keeps Equalweight Rating	MT
23-04-03	Citigroup Adjusts Pulmonx Price Target to $13 From $12, Maintains Buy Rating	MT
23-02-27	Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10	MT
23-02-23	Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating	MT
23-02-23	Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating	MT
23-01-06	Morgan Stanley Adjusts Price Target on Pulmonx to $9.50 From $14, Maintains Equalweight Rating	MT
23-01-03	BofA Securities Downgrades Pulmonx to Underperform From Neutral With $8 Price Target	MT
22-12-12	Wells Fargo Cuts Price Target on Pulmonx to $6 From $13.50, Maintains Equalweight Rating	MT
22-12-12	Citigroup Upgrades Pulmonx to Buy From Neutral, Adjusts Price Target to $10 From $14	MT
22-11-07	Morgan Stanley Adjusts Price Target on Pulmonx to $14 From $19, Maintains Equal-Weight Rating	MT
22-11-04	Piper Sandler Adjusts Price Target on Pulmonx to $13 From $25, Maintains Overweight Rating	MT
22-10-11	Morgan Stanley Adjusts Pulmonx's Price Target to $19 from $21, Reiterates Equalweight Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
PULMONX CORPORATION			+66.67%
PENUMBRA, INC.			+11.45%
GETINGE AB			+0.38%
ASAHI INTECC CO., LTD.			+14.41%
MINIMED GROUP, INC.			+7.14%
APT MEDICAL INC.			+53.93%
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.			+41.82%
NOVOCURE LIMITED			+65.61%
IMPLANTICA AG	-	-	+26.67%
NAKANISHI INC.			+5.29%
Average			+29.34%
Weighted average by Cap.			+19.23%